Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 28, 2015; 21(44): 12558-12575
Published online Nov 28, 2015. doi: 10.3748/wjg.v21.i44.12558
Hepatitis B virus therapy: What’s the future holding for us?
Sobia Manzoor, Muhammad Saalim, Muhammad Imran, Saleha Resham, Javed Ashraf
Sobia Manzoor, Muhammad Saalim, Muhammad Imran, Saleha Resham, Atta-ur-Rahman School of Applied Bio-Sciences, Department of Healthcare Biotechnology, National University of Sciences and Technology, Islamabad 44000, Pakistan
Javed Ashraf, Islam Dental College, Sialkot 51310, Punjab, Pakistan
Author contributions: Manzoor S designed the research; Manzoor S and Saalim M searched the literature and drafted the manuscript; Manzoor S critically reviewed the manuscript; Imran M, Resham S, and Ashraf J helped in literature review and manuscript preparation.
Conflict-of-interest statement: All the authors declare that they have no competing interests.
Data sharing statement: All the data regarding the review is available from the corresponding author, Sobia Manzoor at: lcianunique@yahoo.com.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Sobia Manzoor, PhD, Assistant Professor, Atta-ur-Rahman School of Applied Bio-Sciences, Department of Healthcare Biotechnology, National University of Sciences and Technology, Islamabad 44000, Pakistan. lcianunique@yahoo.com
Telephone: +92-51-90856147 Fax: +92-51-90856102
Received: April 21, 2015
Peer-review started: April 22, 2015
First decision: June 25, 2015
Revised: July 24, 2015
Accepted: October 17, 2015
Article in press: October 20, 2015
Published online: November 28, 2015
Core Tip

Core tip: The need to develop new therapeutic agents for hepatitis B virus treatment is the motivation factor for many research groups and pharmaceutical industries worldwide. The therapies in development from immunomodulation agents to non-nucleoside viral inhibitors hope to replace the current treatments with the promise of increased efficacy, minimum side effects and shorter duration of cure.